SRx Health Solutions Q2 Revenue Rises 23% to $3.4M, EBITDA Loss Narrows
SRx Health Solutions’ Q2 FY26 revenue rose 23% sequentially to $3.4 million, and its adjusted EBITDA loss narrowed 44% to $0.6 million. The firm closed the quarter with $20.5 million cash and cut crypto losses to 21% versus a 27% market drop.
1. Q2 Financial Results
SRx Health Solutions reported Q2 FY26 net revenue of $3.4 million, a 23% sequential increase, with gross profit up 21% to $1.3 million at a 37% margin. Operating loss narrowed 52% to $1.8 million and adjusted EBITDA loss improved 44% to $0.6 million, while loss per share decreased 92% to $0.02.
2. Liquidity and Treasury Strategy
The company bolstered liquidity with $20.5 million in cash and cash equivalents at quarter-end, compared to $1.3 million six months earlier. Short-term investments stood at $3.0 million and digital asset holdings totaled $8.3 million, as the active cryptocurrency strategy limited portfolio losses to 21% versus a 27% market decline.
3. EMJ Crypto Acquisition Outlook
SRx initiated mailing of the information statement for its pending EMJ Crypto Technologies acquisition and expects to complete the deal before fiscal Q3 end. The transaction aims to enhance AI-enabled analytics, strengthen digital asset treasury capabilities and diversify capital base for long-term shareholder value.